



UNIVERSITÀ DEGLI STUDI DI TORINO

This is an author version of the contribution published on:
Molecular and Cellular Endocrinology 22-MAY-2017 pp. 24-31.

DOI information: 10.1016/j.mce.2017.04.013

The definitive version is available at:
<http://dx.doi.org/10.1016/j.mce.2017.04.013>

Spotlight on vitamin D receptor, lipid metabolism and mitochondria: some preliminary emerging issues

*Francesca Silvagno and Gianpiero Pescarmona

Department of Oncology, University of Torino, Via Santena 5 bis, 10126 Torino, Italy.

francesca.silvagno@unito.it

gianpiero.pescarmona@unito.it

*Corresponding author:

Department of Oncology, University of Torino,

Via Santena 5 bis, 10126 Torino, Italy.

francesca.silvagno@unito.it

Phone: +39-011-6705856

Fax: +39-011-6705845

Running title:

Mitochondrial effects of vit.D on lipid metabolism

Abstract

Transcriptional control and modulation of calcium fluxes underpin the differentiating properties of vitamin D ($1,25(\text{OH})_2\text{D}_3$). In the latest years however few studies have pointed out the relevance of the mitochondrial effects of the hormone. It is now time to focus on the metabolic results of vitamin D receptor (VDR) action in mitochondria, which can explain the pleiotropic effects of $1,25(\text{OH})_2\text{D}_3$ and may elucidate few contrasting aspects of its activity. The perturbation of lipid metabolism described in VDR knockout mice and vitamin D deficient animals can be revisited based on the newly identified mechanism of action of $1,25(\text{OH})_2\text{D}_3$ in mitochondria. From the same point of view, the controversial role of $1,25(\text{OH})_2\text{D}_3$ in adipogenesis can be better interpreted.

Keywords: $1,25(\text{OH})_2\text{D}_3$; vitamin D receptor; mitochondrial metabolism; lipid metabolism; vitamin D/VDR deficiency; adipogenesis.

Abbreviations: VDR, vitamin D receptor; RXR, retinoid X receptor; VDR KO, VDR knockout mice; WT, wild type; WAT, white adipose tissue; BAT, Brown adipose tissue; UCP, uncoupling protein; THR, thyroid hormone receptor; PPAR γ , peroxisome proliferator-activated receptor gamma; OCR, oxygen consumption rate; CPT2: carnitine palmitoyltransferase 2; LXR, liver X receptor; DRIP 205/MED1, vitamin D-interacting protein 205/mediator complex subunit 1; TCA cycle, tricarboxylic acid cycle; C/EBP β , CCAAT/enhancer binding protein beta.

1. Introduction

Many biological functions of the active form of vitamin D $1,25(\text{OH})_2\text{D}_3$ are mediated by the control exerted by its receptor VDR on nuclear transcription. VDR acts as a transcription factor, migrating into nuclear compartment upon ligand binding and together with its binding partner retinoid X receptor alpha ($\text{RXR}\alpha$) it recruits coactivators or corepressors to enhance or repress the transcription of many genes. Although $1,25(\text{OH})_2\text{D}_3$ nuclear activity has generally been described as a promoter of differentiation, often the effects exerted by $1,25(\text{OH})_2\text{D}_3$ are not detectable or even opposite [1-2]. A defective nuclear function of VDR has been described as the altered switch between coactivators and corepressors associated to VDR [3,4], but alone this perturbation does not account for the contrasting effects triggered by $1,25(\text{OH})_2\text{D}_3$; moreover the non-genomic activity of VDR, mainly mediated by calcium fluxes, is responsible for additional effects that may change the response to $1,25(\text{OH})_2\text{D}_3$.

$1,25(\text{OH})_2\text{D}_3$ controls calcium homeostasis through genomic and non genomic pathways. As transcriptional factor, vitamin D receptor (VDR) upregulates calcium transporters; for example it induces the expression of the ion channel transient receptor potential vanilloid type 6 (*TRPV6*, the main mediator of calcium transport across the plasmamembrane of intestinal epithelium [5]), and it increases the messenger of the calcium sensing receptor CaR [6], sensitizing the keratinocytes to extracellular calcium and calcium-triggered differentiation.

The main non genomic action of $1,25(\text{OH})_2\text{D}_3$ consists in the regulation of calcium fluxes by direct interaction with plasma membrane proteins. In fact VDR localizes to the caveolar domains of plasma membrane, like other members of the steroid receptor superfamily, and promotes rapid membrane-initiated responses (reviewed in [7,8]). The outcomes of the membrane bound VDR activity influence nuclear transcription; for example the opening of voltage-gated calcium channels [9-12] or the generation of second messengers (as summarized in [13]) contributes to a concerted genomic and non-genomic regulation of many vitamin D-responsive genes. The aim of this review is to widen the analysis of the complex cross-talk between nuclear and extranuclear effects of

1,25(OH)₂D₃ mediated by different VDR pools; for this purpose, we discuss the mitochondrial effects of 1,25(OH)₂D₃ and their metabolic consequences. For further details on the activity of 1,25(OH)₂D₃, the reader is referred to very comprehensive reviews on vitamin D metabolism [14,15], VDR transcriptional activity [16,17] and regulation [18].

2. VDR: a nuclear receptor with a penchant for mitochondria

In addition to the nuclear effects of 1,25(OH)₂D₃, recently a new mechanism of action has been suggested by the described localisation of VDR in mitochondria of platelets, megakaryocytes [19] and keratinocytes [20], where the translocation is mediated by the permeability transition pore activity [20]. Indeed, the mitochondrial function of VDR has been elucidated by subsequent works on cancer cell lines [21], keratinocytes [22] and brown adipocytes [23] that have demonstrated that 1,25(OH)₂D₃ suppresses mitochondrial respiration, hence VDR has been defined a gatekeeper of mitochondrial respiratory chain activity. The consequences of the negative modulation of respiratory chain exerted by VDR are important for cellular bioenergetics as well as for biosynthetic pathways; in fact the mitochondrial activity of 1,25(OH)₂D₃ supports both cell growth and differentiation and this newly discovered metabolic effect relies on the switch from oxidative to biosynthetic metabolism [21,22]. Given its dual nuclear and mitochondrial activity, it is tempting to speculate that 1,25(OH)₂D₃ has a central role both in the regulation of gene sets and in supporting the metabolic requests evoked by nuclear signaling. In fact it is reasonable to think that the mitochondrial activity is modulated in order to adapt cellular metabolism to the nuclear differentiation program or proliferative nuclear signaling.

The metabolism that most obviously is affected by the mitochondrial control is the lipidic one; in fact both the catabolic pathways and the formation of precursors for biosynthetic purposes take place in mitochondria. In this article, we provide an overview of the link between the activity of 1,25(OH)₂D₃ and lipid metabolism, and we put forward new and speculative hypotheses on the effects of VDR signaling in mitochondria, by suggesting that the combined nuclear and

mitochondrial action of $1,25(\text{OH})_2\text{D}_3$ might support the metabolism of the adipose tissue and skin as well as many others.

3. The lessons learned from VDR knockout mice

Due to the central role of $1,25(\text{OH})_2\text{D}_3$ in calcium homeostasis and deposition in bones, the silencing of VDR in knockout (KO) mice causes a defective calcium absorption and skeletal remodeling. Three independent models of VDR null mice were generated by disruption of the DNA binding domain of VDR, ablating either the first or the second zinc finger (exon 2 and 3, respectively) (Tokyo [24], Boston [25], Leuven [26] models); a fourth group (Munich model [27]) produced a mouse that expressed a VDR protein with a deletion of the first zinc finger, thus unable to bind DNA, but with normal ligand binding affinity. All the models developed hypocalcemia, hypophosphatemia, secondary hyperparathyroidism, severe rickets and osteomalacia [24-27] due to the lack of functional VDR. Also the non-genomic effects of VDR were lost [27]. Besides the expected hypocalcemic and bone defective phenotype, VDR knockout mice are a good model to study the impact of VDR-mediated $1,25(\text{OH})_2\text{D}_3$ activity in extra-skeletal tissues and general metabolism in vivo, including the role of $1,25(\text{OH})_2\text{D}_3$ and VDR in adipogenesis and lipid metabolism. Two studies investigated the metabolic phenotype of VDR-null mutant mice [28,29] in the Boston model [25]. In these mice the genetic alteration results in a frame shift followed by premature termination codon, which generates an apparent instability of the VDR transcript [25]. These animals exhibited decreased body weight, diminished body fat, reduced serum levels of leptin and lipids (triglycerides and cholesterol), while the calorimetric parameters such as energy expenditure, oxygen consumption and CO_2 production were increased. At the cellular level, beta-oxidation was higher in white adipose tissue (WAT), and the expression of carnitine palmitoyltransferase 2 (CPT2, the mitochondrial transporter of fatty acids) was increased in the knockout animals, compared to the wild type (WT) littermates [28]. An increase in the expression of all uncoupling proteins (UCP) in the brown adipose tissue (BAT) was also observed in the VDR

KO mice, suggesting an enhanced energy uncoupling in these cells and higher basal energy expenditure. Accordingly, treatment of brown adipocytes with $1,25(\text{OH})_2\text{D}_3$ downregulated the expression of all three UCPs [28]. The inhibitory effect of VDR on UCP expression has been demonstrated in studies carried out in human adipose tissues [29] and in hereditary vitamin D-resistant rickets [30] establishing VDR as a modulator of energy balance in humans. The metabolic and molecular perturbations found in primary adipocytes and in the KO mice suggest key action of liganded VDR in the mitochondria and explain the lower adipose mass and lower plasma lipid profile in the mutant mice.

A similar lean phenotype was also described in mice lacking the 1α -hydroxylase enzyme that generates $1,25(\text{OH})_2\text{D}_3$ [31], supporting the important role of $1,25(\text{OH})_2\text{D}_3$ in lipid metabolism.

The lean phenotype found in VDR KO model has the same traits as the hyperthyroid metabolism described in humans and in mice models of hyperthyroidism [32-35]. This similarity could be explained by hypothesizing a competition between VDR and thyroid hormone receptors (THR) on cofactors or binding partners that would become limiting in the activity of the hormones. This could be the case for RXR alpha, the heterodimerization partner of many steroid receptors; the competition over RXR has been demonstrated not only for VDR and THR [36] but also for other members of the steroid/nuclear hormone receptor superfamily, such as peroxisome proliferator-activated receptors (PPAR) and liver X receptor (LXR) [37-40]. Another limiting candidate could be the coactivator DRIP 205/MED1 (vitamin D-interacting protein 205/mediator complex subunit 1), which is necessary for transcriptional activity of both VDR and THR [41,42]. Therefore the lean phenotype of VDR KO mice could be the result of a direct effect of VDR silencing and a potentiated action of thyroid hormone.

The observations made in VDR KO mice are confirmed by the opposite results obtained in the transgenic mouse model overexpressing the human VDR specifically in the adipose tissue [43], which gains adipose mass and reduces energy metabolism compared with the WT counterpart. In direct opposition to what described for VDR KO mice, in the transgenic model the investigators

found reduced leptin levels, increased circulating cholesterol and decreased calorimetric parameters. The overexpression of VDR in the adipocytes led to reduced UCP expression, decreased beta-oxidation and lipolysis, and glucose intolerance. The metabolic derangement was accompanied by suppression of key genes involved in these processes (hexokinase, carnitine palmitoyl transferases, lipases). Interestingly enough, when the effect of $1,25(\text{OH})_2\text{D}_3$ was analysed in two adipocyte cell lines, a direct transcriptional control of these enzymes was not evident, rather suggesting that $1,25(\text{OH})_2\text{D}_3$ influences fatty acid transport, catabolism and glycolysis by indirectly regulating these genes [43].

In conclusion, the analysis of VDR KO and transgenic mice demonstrated that the mitochondrial action of $1,25(\text{OH})_2\text{D}_3$ is exerted on catabolism of fatty acids and uncoupling. $1,25(\text{OH})_2\text{D}_3$ reduces lipid utilization from depots and decreases the energy and heat dissipation due to uncoupling process. As a consequence, VDR ablation leads to the lean phenotype. The precise mechanism through which VDR can control lipid catabolism remained elusive.

$1,25(\text{OH})_2\text{D}_3$ controls lipid metabolism also in the skin. VDR KO mice have also defects in permeability barrier homeostasis due to a disrupted barrier formation, lipid secretion, and lipid composition [44]. The importance of $1,25(\text{OH})_2\text{D}_3$ and VDR in the regulation of permeability barrier formation is supported also by the observations made in mice deficient in 1α -hydroxylase; these animals show an impaired barrier repair after acute disruption due to a decrease in lamellar body secretion [45].

4. The effects of $1,25(\text{OH})_2\text{D}_3$ and VDR on mitochondrial activity: the consequences on lipid metabolism

Recent studies have described the influence of $1,25(\text{OH})_2\text{D}_3$ on mitochondrial activity. A first work has demonstrated that in the human keratinocyte cell line HaCaT the VDR can downregulate the transcription of proteins of the respiratory chain and can decrease the mitochondrial membrane potential, in other words VDR restrains the activity of mitochondrial respiratory chain [21]. This

conclusion is supported by the data presented in another study [23] that measured cellular bioenergetics coupled with mitochondrial stress tests by a XF24 Extracellular Flux Analyzer. The study investigated mitochondrial respiration in 1,25(OH)₂D₃-treated human brown adipocytes and demonstrated that 1,25(OH)₂D₃ suppresses basal oxygen consumption rate (OCR), maximal OCR and OCR from proton leak. The metabolic modulation exerted by 1,25(OH)₂D₃/VDR sustains cell proliferation, and indeed several cancer cell lines silenced for VDR are inhibited in their growth [21]. One of the consequences of VDR-induced brake on respiratory chain is the rerouting of mitochondrial acetyl-CoA towards biosynthesis. In proliferating cells the diversion benefits mainly the cholesterol production necessary to proliferation [21], thus the metabolic modulation exerted by 1,25(OH)₂D₃/VDR sustains cell growth, and indeed several cancer cell lines silenced for VDR are inhibited in their growth [21]. By contrast, in differentiated keratinocytes that upregulate the fatty acid biosynthetic pathway the metabolic switch promotes lipid deposition [22]. We can conclude that the effects of 1,25(OH)₂D₃ on mitochondria support differently the metabolism of differentiated and proliferating human cells.

At present, with this novel insight into the modalities of 1,25(OH)₂D₃ action, we can better understand the observations made in VDR KO and 1,25(OH)₂D₃-deficient models by reinterpreting the metabolic data and formulating new hypothesis, summarized in figure 1. VDR downregulates respiratory chain activity, curtails the utilization of reducing units and slows down beta-oxidation. As consequence, the mitochondrial activity of VDR decreases lipid catabolism and promotes the channeling of acetyl-CoA into biosynthetic pathways (figure 1A). Indeed the consequences of VDR overexpression are the increased adipose mass and the reduced energy metabolism observed in the transgenic mouse model [43]. When VDR activity is lost, in knockout or diet-deficient animals, the mitochondrial respiratory activity is enhanced and UCPs expression is higher, leading to the observed increased calorimetric parameters [28,29]. The dual control of VDR on respiratory chain and UCPs expression is interesting and makes sense, in order to avoid unnecessary uncoupling and finely tune a proton gradient which cannot rely only on ATPase activity. Because of this concerted

control, the formation and dissipation of proton gradient is balanced. When VDR is ablated, the increased respiratory activity enhances the TCA cycle and beta-oxidation rises. The low levels of cytosolic malonil-CoA (derived from acetyl-CoA) relieve the inhibition of fatty acid mitochondrial import (figure 1B); as consequence, fat is mobilized from depots and catabolized in mitochondria. The cachectic phenotype observed in $1,25(\text{OH})_2\text{D}_3$ -deficient animals is another consequence of the increased oxidative metabolism, because muscle wasting is due to aminoacid utilization in TCA cycle.

5. $1,25(\text{OH})_2\text{D}_3$ activity and adipogenesis

When the effects of $1,25(\text{OH})_2\text{D}_3$ activity are investigated in vitro, both adipogenesis and adipocyte differentiation appear to be affected by the hormone, but the observations reach conflicting conclusions depending on the cellular model investigated.

The genome-wide studies based on next-generation sequencing have demonstrated the important role of histone modifications and epigenetic modulators in adipogenesis, and have added new details on how the cellular context (for example in response to thermogenic signals) can change the genomic programming of adipocytes (reviewed in [46]).

Also the genomic effects of $1,25(\text{OH})_2\text{D}_3$ are strongly influenced by the cellular setting. The most recent genome-wide analysis of the $1,25(\text{OH})_2\text{D}_3$ -modulated transcriptome have highlighted the complexity of events that determine the recruitment of VDR/RXR heterodimers and co-activators to binding sites often located in the enhancer regions of genes, and have described the interaction with general regulators of the chromatin remodeling process (reviewed in [47]). The VDR cistrome profile is lineage specific and it is modulated by the cellular status. For example the cellular differentiation dictates a remarkable quantitative and qualitative change of the transcriptional control exerted by $1,25(\text{OH})_2\text{D}_3$. The studies on osteoblast differentiation [48-51] have described the reduction and modification of VDR-dependent transcriptome in differentiated cells: many genes become resistant to $1,25(\text{OH})_2\text{D}_3$ stimulation and others change their transcriptional response; the

reasons of this plasticity related to cellular status can reside in the enrichment of transcription factors at nearby sites that can influence VDR activity and in the rearranged epigenetic landscape that can modify the access of VDR to binding motives close to target genes. In turn, bound VDR can influence the epigenetic profile of the cell and facilitate cellular transition [47,52].

Few studies have described the inhibitory effect of $1,25(\text{OH})_2\text{D}_3$ on adipogenesis. The analysis of the mechanisms underpinning differentiation has been often carried out on the preadipocyte cellular model 3T3-L1 cell line, which can be terminally differentiated into mature adipocytes [53]. At time zero, the cells are treated with prodifferentiative agents (insulin, glucocorticoids, and phosphodiesterase inhibitor) that induce two rounds of cell division, and after two days the cells are switched to a differentiation medium containing only insulin. Several studies using the murine 3T3-L1 preadipocyte cell line have investigated the major transcriptional players in adipogenesis [54,55]. The early clonal expansion is driven by C/EBP β (CCAAT/enhancer binding protein beta) [56] and glucocorticoid receptor, followed by a second cascade of transcription factors such as PPAR γ , which is a primary driver of the adipocyte gene program. In the later stage the differentiated cells express the markers characteristic of adipocyte phenotype. $1,25(\text{OH})_2\text{D}_3$ inhibits in a dose-dependent manner the early events of the adipogenic program (the first 48 hours), whereas it is ineffective if administered in the late phase of the differentiation protocol [2]. The effect is mediated by the stabilization of VDR protein, by the suppression of PPAR γ upregulation and the antagonization of PPAR γ activity [2, 57]. The activities of VDR and PPAR γ are linked and influence each other. Indeed VDR overexpression suppresses PPAR γ transactivation in brown preadipocytes [23] and this negative modulation has been reported for another member of the PPAR family [58]. On the other hand, the overexpression of PPAR γ attenuates $1,25(\text{OH})_2\text{D}_3$ -mediated transactivation of VDR and competes with VDR for their binding partner RXR α [37]. Moreover $1,25(\text{OH})_2\text{D}_3$ downregulates C/EBP β gene expression in differentiating 3T3-L1 cells [1]. Other studies carried out in a line of brown adipocytes [23] and in the femoral bone marrow derived

cell line (BMS2) [59] confirmed that $1,25(\text{OH})_2\text{D}_3$ suppresses adipogenesis in the early phase of the differentiation process and the effect disappears if the cells are treated after day two of the differentiation protocol. Based on these observations we can conclude that $1,25(\text{OH})_2\text{D}_3$ acts as anti-differentiating agent only in the early events of a differentiation protocol applied to proliferating cell lines, by interfering with the activity of key transcription factors.

On the other hand, the data collected from primary models used in adipogenesis studies show that in primary cells committed to adipocyte lineage the $1,25(\text{OH})_2\text{D}_3$ exerts a differentiating adipogenic effect. Few established models to study adipogenesis start from primary bone cultures in which progenitor cells are committed to several mesenchymally derived cell types. In freshly isolated fetal rat calvaria (RC) cell populations the adipocyte differentiation is stimulated by $1,25(\text{OH})_2\text{D}_3$ [60,61]. Moreover the treatment with the hormone increases the frequency of osteoblast/adipocyte bipotential progenitors and the number of colonies stained for lipids [62]. The primary bone marrow stromal cells are sensitive to $1,25(\text{OH})_2\text{D}_3$ treatment that stimulates adipocytic cell differentiation [63]. $1,25(\text{OH})_2\text{D}_3$ stimulates adipogenesis also in mesenchymal progenitor cells derived from normal human adipose tissue [64]. Microarray analysis of the adipogenic process showed that nuclear signaling of VDR, while promoting adipogenic differentiation, downregulates genes involved in differentiation into other lineages [64].

In conclusion, the effect of $1,25(\text{OH})_2\text{D}_3$ on adipogenesis is opposite whether the cellular model analysed is a proliferating preadipocyte cell line or a committed primary culture of progenitor cells. The differences between the models can be ascribed to the lineage-specific chromatin remodeling taking place during differentiation protocols, which can determine the variability of VDR cistrome. A different recruitment of VDR and co-activators to DNA can have opposite effects on gene transcription. In addition to the genomic effects of its receptor, we must also consider the results of $1,25(\text{OH})_2\text{D}_3$ activity on cellular metabolism. Based on the observation that the effects of $1,25(\text{OH})_2\text{D}_3$ on mitochondria support differently the metabolism of differentiated and proliferating human keratinocytes [21,22], as discussed in section four, similar conclusions can be drawn on

adipogenesis, keeping in mind that the metabolic effects of $1,25(\text{OH})_2\text{D}_3$ sustain the nuclear programming. We propose an integrated genomic and metabolic view that can conciliate the dual effect of $1,25(\text{OH})_2\text{D}_3$ on adipogenesis; in our model, depicted in figure 2, the chromatin reorganization triggered by environmental clues influences VDR cistrome, so that VDR is effective on selected genes required by the cellular context, either proliferation or differentiation. At the same time, the effects of $1,25(\text{OH})_2\text{D}_3$ on mitochondrial metabolism support the specific gene expression profile. When the adipogenesis of a preadipocyte cell line is considered, in the early phase of a differentiation protocol the stimulation with glucocorticoids, insulin and phosphodiesterase inhibitor maintains a proliferative asset; in this phase $1,25(\text{OH})_2\text{D}_3$ sustains proliferation since acetyl-CoA can be diverted toward cholesterol biosynthesis. As consequence, in this model the outcome of $1,25(\text{OH})_2\text{D}_3$ treatment in the early phase of differentiation is a decreased lipid deposition (figure 2A). In the late events of differentiation, when the cultural conditions change and adipogenesis is consolidated, the treatment with $1,25(\text{OH})_2\text{D}_3$ can support the differentiated state by diverting acetyl-CoA into fatty acid biosynthesis. The VDR seems necessary for lipid accumulation in the late phase, since knock-down of the VDR both delays and prevents this process [1,64]. This happens despite the low levels of VDR found in differentiated 3T3-L1 cells [1,2], suggesting that even barely detectable amount of the receptor are sufficient and necessary to support the adipogenic function.

Instead, when the differentiation protocol is applied to primary cultures from bone, a model in which progenitor cells are committed to the adipocyte lineage, $1,25(\text{OH})_2\text{D}_3$ supports a nuclear differentiation program and facilitates lipid deposition because the mitochondrial acetyl-CoA can be used in the fatty acid biosynthetic pathway (figure 2B). In all cases, the metabolic response to $1,25(\text{OH})_2\text{D}_3$ /VDR activity is the increased availability of acetyl-CoA for biosynthetic purposes, but the epigenetic reprogramming could be responsible for the biosynthetic fate of this precursor: for example the prevalence of SREBP-1 or SREBP-2 activity due to chromatin remodeling could potentiate lipogenesis or cholesterologenesis, respectively. In fact several data suggest that SREBP-

1 primarily regulates fatty acid metabolism and that SREBP-2 is the main regulator of cholesterol metabolism [65]. Few studies reported a differential accumulation of SREBP-1 or SREBP-2 under different dietary conditions consistently with each factor performing a preferred metabolic function in lipogenesis or cholesterologenesis in the liver [66-68]. A comparison of the genome-wide binding profiles for SREBP-1 and SREBP-2 in hepatic chromatin revealed that only 11.7 % of their binding sites overlap and demonstrated that under specific conditions they bind mostly to different sets of target sites in the liver genome [69]. Future genome-wide studies should integrate the VDR cistrome analysis with the examination of the binding profile of the key transcription factors in adipogenesis.

6. 1,25(OH)₂D₃ deficiency in murine models and men: cachectic versus obese phenotype

The lean phenotype observed in VDR KO animals is found also in rats fed with a 1,25(OH)₂D₃-deficient diet [70]. The two models show overlapping parameters, although with few differences due to calcium imbalance. In fact, whereas VDR KO animals are fed a diet enriched in calcium, indeed to avoid indirect metabolic effects, the dietary lack of 1,25(OH)₂D₃ induces a perturbed calcium homeostasis that makes results difficult to interpret; the addition of calcium in this diet reverts partially the effects and adds new metabolic variables, such as the increase in insulin levels. The common features of animals deficient either in 1,25(OH)₂D₃ or its receptor are the decreased body weight and fat, the reduced levels of leptin and increased expression of uncoupling proteins. Whereas in VDR KO is evident the enhanced utilization of fat from depots, in 1,25(OH)₂D₃-deficient animals there are also the signs of reduced adipogenesis, because the transcription of PPAR γ and fatty acid synthase is decreased [70]. 1,25(OH)₂D₃ deficiency affects also muscular tissues, which decrease their mass similarly to fat depots. Muscle wasting in 1,25(OH)₂D₃-deficient rats is due to increased muscle protein breakdown [71]. Therefore 1,25(OH)₂D₃ deficiency leads to an unhealthy lean and cachectic phenotype characterized by muscle wasting and reduced adiposity.

If low levels of $1,25(\text{OH})_2\text{D}_3$ or its receptor lead to the lean phenotype, it would be reasonable to expect the opposite result when a diet is fortified with $1,25(\text{OH})_2\text{D}_3$. On the other hand, $1,25(\text{OH})_2\text{D}_3$ increases calcium absorption and enhances intracellular calcium utilization, and this could stimulate the cellular energy expenditure, could activate the basal metabolism and facilitate a lean phenotype. The effects of $1,25(\text{OH})_2\text{D}_3$ supplementation have been investigated in models of obesity induced by the high fat diet. These studies have reached conflicting conclusions, also because different animal models and different supplemented diets have been used. The long-term (one year) feeding of mice with a diet high in fat and low in vitamin D_3 (the precursor of $1,25(\text{OH})_2\text{D}_3$), calcium, methyl donors and fiber leads to reduced energy expenditure and oxygen consumption, impaired glucose clearance and an elevated systemic inflammatory response. In this model, elevating dietary vitamin D_3 and calcium increases weight gain, fat deposition, and worsens the metabolic syndrome [72]. In contrast, both a mice and a rat model fed for a shorter time (ten or eight weeks) with a high fat diet benefit from $1,25(\text{OH})_2\text{D}_3$ treatment, since $1,25(\text{OH})_2\text{D}_3$ supplementation in mice protects against diet-induced obesity, improves glucose homeostasis and lipid oxidation [73], and reduces body weight gain, inhibits lipogenesis and promotes fatty acid oxidation in rat liver [74].

Clearly, in humans it is not possible to reproduce a VDR KO model. However, a primary deficiency or the resistance to $1,25(\text{OH})_2\text{D}_3$ is found in some diseases: rickets, for example; unfortunately the lipid metabolism has not been investigated in these subjects.

Clinical studies correlate obesity with $1,25(\text{OH})_2\text{D}_3$ deficiency [75-81]; this link is possibly due to a reduced synthesis of the active form of vitamin D in obese individuals, or to the sequestration of $1,25(\text{OH})_2\text{D}_3$ in the increased fat tissue found in obesity. Indeed there are evidences that obesity is characterized by a decreased expression of the two biosynthetic enzymes of $1,25(\text{OH})_2\text{D}_3$ metabolism, the 25-hydroxylase and the 1α -hydroxylase, in human adipose tissue [82]. Moreover the high fat diet in mice resulted in a decrease of $25(\text{OH})$ -vitamin D plasma level [73]. Therefore it seems reasonable to hypothesize that obesity and metabolic syndrome are promoters of

1,25(OH)₂D₃ deficiency, although it is unknown the mechanism by which the perturbed lipid homeostasis would affect the biosynthetic enzymes. This view is endorsed by the recent bi-directional Mendelian randomization analysis of 21 adult cohorts, which has demonstrated that higher BMI (body mass index) leads to lower 1,25(OH)₂D₃ status, whereas there is no evidence for a causal role of 1,25(OH)₂D₃ deficiency in the development of obesity [83]. The fact that low levels of 1,25(OH)₂D₃ are not causative of obesity is supported by the irrelevance of 1,25(OH)₂D₃ supplementation in clinical trials of obese patients [84-87].

7. Concluding remarks and future perspectives

Recent studies have highlighted the relevance of 1,25(OH)₂D₃ activity on mitochondrial metabolism, suggesting that many previously described metabolic effects of 1,25(OH)₂D₃ on adipose tissue could be the result of mitochondrial modulation.

1,25(OH)₂D₃ exerts a concerted action on nuclear and mitochondrial compartment, and facilitates the adaptation of the mitochondrial metabolism to the phenotype generated by nuclear inputs. The consequences of 1,25(OH)₂D₃ action on adipogenesis are dual, because the hormone can support both the proliferative phase and the differentiation process of the precursors of adipocytes.

In differentiated tissues 1,25(OH)₂D₃ sustains a physiological mitochondrial lipid metabolism by two main mechanisms:

(1) the vitamin D-dependent calcium uptake in tissues enhances lipid catabolism. In fact it has been demonstrated that high dietary calcium increases fat oxidation rate and that low calcium intake can be associated with higher body fatness (reviewed in [88]). 1,25(OH)₂D₃ stimulates intestinal calcium absorption and renal calcium reabsorption, in order to maintain the serum levels of calcium. Also calcium utilization in tissues is influenced by the hormone. Actually many of the metabolic effects of 1,25(OH)₂D₃ are mediated by calcium, as demonstrated by the fact that most of the changes observed in 1,25(OH)₂D₃ deficient rats were corrected by calcium supplementation alone [70]. In support of the calcium-mediated beneficial effects of 1,25(OH)₂D₃, few studies have reported that

the supplementation with $1,25(\text{OH})_2\text{D}_3$ in association with calcium decreases fat mass in obese patients [89,90] and affects glucose metabolism and lipid concentrations in overweight and obese vitamin D deficient women [91].

(2) $1,25(\text{OH})_2\text{D}_3$ exerts a negative transcriptional control on respiratory chain elements and uncoupling proteins, in order to withhold respiratory activity and minimize the uncoupling process; thus by optimizing the respiratory performance $1,25(\text{OH})_2\text{D}_3$ avoids the unnecessary catabolic fuelling that would lead to an unhealthy lean cachectic phenotype. This negative control of respiratory activity could be superimposed on the antagonism between VDR and THR. Their competition for binding partners and co-activators would make their alternation beneficial to the optimal respiratory rate.

In conclusion, $1,25(\text{OH})_2\text{D}_3$ is necessary to accumulate lipids and to burn them properly. The effects of $1,25(\text{OH})_2\text{D}_3$ supplementation could be different depending on dietary calcium content plus the individual metabolic phenotype and hormonal balance. Under this perspective, it will be very important for future therapeutic strategies to understand what are the causes of reduced biosynthesis of $1,25(\text{OH})_2\text{D}_3$ in obesity and why $1,25(\text{OH})_2\text{D}_3$ is scarcely effective in reducing fat depots in obesity.

Acknowledgements

This work has been supported by Ministero dell'Istruzione Università e Ricerca.

Conflict of interest

The authors declare no conflict of interest.

References

- 1 Blumberg JM, Tzameli I, Astapova I, Lam FS, Flier JS, Hollenberg AN. 2006. Complex role of the vitamin D receptor and its ligand in adipogenesis in 3T3-L1 cells. *J. Biol. Chem.* 281, 11205–11213.
- 2 Kong J. and Li YC. 2006. Molecular mechanism of 1,25-dihydroxyvitamin D₃ inhibition of adipogenesis in 3T3-L1 cells. *Am. J. Physiol. Endocrinol. Metab.* 290, E916–E924.
- 3 Bikle DD, Oda Y, Xie Z. 2005. Vitamin D and skin cancer: a problem in gene regulation. *J Steroid Biochem Mol Biol.* 97, 83–91.
- 4 Abedin SA, Banwell CM, Colston KW, Carlberg C, Campbell MJ. 2006. Epigenetic corruption of VDR signalling in malignancy. *Anticancer Res.* 26, 2557–2566.
- 5 Walters JR, Balesaria S, Chavele KM, Taylor V, Berry JL, Khair U, Barley NF, van Heel DA, Field J, Hayat JO, Bhattacharjee A, Jeffery R, Poulosom R. 2006. Calcium channel TRPV6 expression in human duodenum: different relationships to the vitamin D system and aging in men and women. *J Bone Miner Res.* 21:1770-1777.
- 6 Ratnam AV, Bikle DD, Cho JK. 1999. 1,25 dihydroxyvitamin D₃ enhances the calcium response of keratinocytes. *J. Cell Physiol.* 178,188-196.
- 7 Levin ER, Hammes SR. 2016. Nuclear receptors outside the nucleus: extranuclear signalling by steroid receptors. *Nat Rev Mol Cell Biol.* 17, 783-797.
- 8 Mizwicki MT, Norman AW. 2009. The vitamin D sterol-vitamin D receptor ensemble model offers unique insights into both genomic and rapid-response signaling. *Sci Signal.* 2, re4.
- 9 Norman AW, Okamura WH, Hammond MW, Bishop JE, Dormanen MC, Bouillon R, van Baelen H, Ridall AL, Daane E, Khoury R, Farach-Carson MC. 1997. Comparison of 6-s-cis- and 6-s-trans-locked analogs of 1 α ,25-dihydroxyvitamin D₃ indicates that the 6-s-cis conformation is preferred for rapid nongenomic biological responses and that neither 6-s-cis- nor 6-s-trans-locked analogs are preferred for genomic biological responses. *Mol. Endocrinol.* 11, 1518-1531.

- 10 Bravo S, Paredes R, Izaurieta P, Lian JB, Stein JL, Stein GS, Hinrichs MV, Olate J, Aguayo LG, Montecino M. 2006. The classic receptor for 1 α ,25-dihydroxy vitamin D₃ is required for non-genomic actions of 1 α ,25-dihydroxy vitamin D₃ in osteosarcoma cells. *J. Cell Biochem.* 99, 995-1000.
- 11 de Boland AR, Nemere I, Norman AW. 1990. Ca²⁺(+)-channel agonist BAY K8644 mimics 1,25(OH)₂-vitamin D₃ rapid enhancement of Ca²⁺ transport in chick perfused duodenum. *Biochem. Biophys. Res. Commun.* 166, 217-222.
- 12 Kajikawa M, Ishida H, Fujimoto S, Mukai E, Nishimura M, Fujita J, Tsuura Y, Okamoto Y, Norman AW, Seino Y. 1999. An insulintropic effect of vitamin D analog with increasing intracellular Ca²⁺ concentration in pancreatic beta-cells through nongenomic signal transduction. *Endocrinology* 140, 4706–4712.
- 13 Hii CS, Ferrante A. 2016. The Non-Genomic Actions of Vitamin D. *Nutrients.* 8:135.
- 14 Christakos S, Dhawan P, Verstuyf A, Verlinden L, Carmeliet G. 2016. Vitamin D: Metabolism, Molecular Mechanism of Action, and Pleiotropic Effects. *Physiol Rev.* 96:365-408.
- 15 Bikle DD. 2014. Vitamin D metabolism, mechanism of action, and clinical applications. *Chem Biol.* 21,319-329.
- 16 Pike JW, Meyer MB, Lee SM, Onal M, Benkusky NA. 2017. The vitamin D receptor: contemporary genomic approaches reveal new basic and translational insights. *J Clin Invest.* 127, 1146-1154.
- 17 Haussler MR, Whitfield GK, Kaneko I, Haussler CA, Hsieh D, Hsieh JC, Jurutka PW. 2013. Molecular mechanisms of vitamin D action. *Calcif Tissue Int.* 92, 77-98.
- 18 Saccone D, Asani F1, Bornman L. 2015. Regulation of the vitamin D receptor gene by environment, genetics and epigenetics. *Gene.* 561, 171-180.
- 19 Silvagno F, De Vivo E, Attanasio A, Gallo V, Mazzucco G, Pescarmona G, 2010. Mitochondrial localization of vitamin D receptor in human platelets and differentiated megakaryocytes. *PLoS One* 5, e8670.

- 20 Silvagno F, Consiglio M, Foglizzo V, Destefanis M, Pescarmona G. 2013. Mitochondrial translocation of vitamin D receptor is mediated by the permeability transition pore in human keratinocyte cell line. *PLoS One* 8, e54716.
- 21 Consiglio M, Destefanis M, Morena D, Foglizzo V, Forneris M, Pescarmona G, Silvagno F. 2014. The vitamin D receptor inhibits the respiratory chain, contributing to the metabolic switch that is essential for cancer cell proliferation. *PLoS One* 9, e115816.
- 22 Consiglio M, Viano M, Casarin S, Castagnoli C, Pescarmona G, Silvagno F. 2015. Mitochondrial and lipogenic effects of vitamin D on differentiating and proliferating human keratinocytes. *Exp. Dermatol.* 24, 748-753.
- 23 Ricciardi CJ, Bae J, Esposito D, Komarnytsky S, Hu P, Chen J, Zhao L. 2015. 1,25-Dihydroxyvitamin D₃/vitamin D receptor suppresses brown adipocyte differentiation and mitochondrial respiration. *Eur. J. Nutr.* 54, 1001-1012.
- 24 Yoshizawa T, Handa Y, Uematsu Y, Takeda S, Sekine K, Yoshihara Y, Kawakami T, Arioka K, Sato H, Uchiyama Y, Masushige S, Fukamizu A, Matsumoto T, Kato S. 1997. Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning. *Nat Genet.* 16:391–396.
- 25 Li YC, Pirro AE, Amling M, Delling G, Baron R, Bronson R, Demay MB. 1997. Targeted ablation of the vitamin D receptor: an animal model of vitamin D-dependent rickets type II with alopecia. *Proc Natl Acad Sci USA.* 94:9831–9835.
- 26 Van Cromphaut SJ, Dewerchin M, Hoenderop JG, Stockmans I, Van Herck E, Kato S, Bindels RJ, Collen D, Carmeliet P, Bouillon R, Carmeliet G. 2001. Duodenal calcium absorption in vitamin D receptor-knockout mice: functional and molecular aspects. *Proc Natl Acad Sci USA.* 98:13324–13329.
- 27 Erben RG, Soegiarto DW, Weber K, Zeitz U, Lieberherr M, Gniadecki R, Moller G, Adamski J, Balling R. 2002. Deletion of deoxyribonucleic acid binding domain of the vitamin D receptor abrogates genomic and nongenomic functions of vitamin D. *Mol Endocrinol.* 16:1524 –1537.

- 28 Wong KE, Szeto FL, Zhang W, Ye H, Kong J, Zhang Z, Sun XJ, Li YC. 2009. Involvement of the vitamin D receptor in energy metabolism: regulation of uncoupling proteins. *Am. J. Physiol. Endocrinol. Metab.* 296, E820-828.
- 29 Shi H, Norman AW, Okamura WH, Sen A, Zemel MB. 2002. 1 α ,25-dihydroxyvitamin D₃ inhibits uncoupling protein 2 expression in human adipocytes. *Faseb J.* 16, 1808–1810.
- 30 Malloy PJ, Feldman BJ. 2013. Cell-autonomous regulation of brown fat identity gene UCP1 by unliganded vitamin D receptor. *Mol Endocrinol.* 27, 1632-1642.
- 31 Narvaez CJ, Matthews D, Broun E, Chan M, Welsh J. 2009. Lean phenotype and resistance to diet-induced obesity in vitamin D receptor knockout mice correlates with induction of uncoupling protein-1 in white adipose tissue. *Endocrinology.* 150, 651-661.
- 32 Kita M, Ahmad L, Marians RC, Vlase H, Unger P, Graves PN, Davies TF. 1999. Regulation and transfer of a murine model of thyrotropin receptor antibody mediated Graves' disease. *Endocrinology.* 140, 1392-1398.
- 33 Kaithamana S, Fan J, Osuga Y, Liang SG, Prabhakar BS. 1999. Induction of Experimental Autoimmune Graves' Disease in BALB/c Mice. *J. Immunol.* 163, 5157-5164.
- 34 Lahesmaa M, Orava J, Schalin-Jääntti C, Soinio M, Hannukainen JC, Noponen T, Kirjavainen A, Iida H, Kudomi N, Enerbäck S, Virtanen KA, Nuutila P. 2014. Hyperthyroidism increases brown fat metabolism in humans. *J. Clin. Endocrinol. Metab.* 99, E28-E35.
- 35 Riis AL, Gravholt CH, Djurhuus CB, Nørrelund H, Jørgensen JO, Weeke J, Møller N. 2002. Elevated regional lipolysis in hyperthyroidism. *J Clin Endocrinol Metab.* 87, 4747-4753.
- 36 Raval-Pandya M, Freedman LP, Li H, Christakos S. 1998. Thyroid hormone receptor does not heterodimerize with the vitamin D receptor but represses vitamin D receptor-mediated transactivation. *Mol Endocrinol.* 12,1367-1379.
- 37 Alimirah F, Peng X, Yuan L, Mehta RR, von Knethen A, Choubey D, Mehta RG. 2012. Crosstalk between the peroxisome proliferator-activated receptor γ (PPAR γ) and the vitamin D

receptor (VDR) in human breast cancer cells: PPAR γ binds to VDR and inhibits 1 α ,25-dihydroxyvitamin D3 mediated transactivation. *Exp. Cell Res.* 318, 2490-2497.

38 Matsusue K, Miyoshi A, Yamano S, Gonzalez FJ. 2006. Ligand-activated PPARbeta efficiently represses the induction of LXR-dependent promoter activity through competition with RXR. *Mol. Cell Endocrinol.* 256, 23-33.

39 Balanarasimha M, Davis AM, Soman FL, Rider SD Jr, Hostetler HA. 2014. Ligand-regulated heterodimerization of peroxisome proliferator-activated receptor α with liver X receptor α . *Biochemistry.* 53, 2632-2643.

40 Wang L, Shao YY, Ballock RT. 2005. Peroxisome proliferator activated receptor-gamma (PPARgamma) represses thyroid hormone signaling in growth plate chondrocytes. *Bone.* 37, 305-312.

41 Fondell JD. 2013. The Mediator complex in thyroid hormone receptor action. *Biochim. Biophys. Acta.* 1830, 3867-3875.

42 Oda Y, Chalkley RJ, Burlingame AL, Bikle DD. 2010. The transcriptional coactivator DRIP/mediator complex is involved in vitamin D receptor function and regulates keratinocyte proliferation and differentiation. *J. Invest. Dermatol.* 130, 2377-2388.

43 Wong KE, Kong J, Zhang W, Szeto FL, Ye H, Deb DK, Brady MJ, Li YC. 2011. Targeted expression of human vitamin D receptor in adipocytes decreases energy expenditure and induces obesity in mice. *J. Biol. Chem.* 286, 33804-33810.

44 Oda Y, Uchida Y, Moradian S, Crumrine D, Elias PM, Bikle DD. 2009. Vitamin D receptor and coactivators SRC2 and 3 regulate epidermis-specific sphingolipid production and permeability barrier formation. *J. Invest. Dermatol.* 129, 1367–1378.

45 Bikle DD, Chang S, Crumrine D, Elalieh H, Man MQ, Choi EH, Dardenne O, Xie Z, Arnaud RS, Feingold K, Elias PM. 2004. 25 Hydroxyvitamin D 1 alpha-hydroxylase is required for optimal epidermal differentiation and permeability barrier homeostasis. *J. Invest. Dermatol.* 122, 984–992.

- 46 Loft A, Forss I, Mandrup S. 2017. Genome-Wide Insights into the Development and Function of Thermogenic Adipocytes. *Trends Endocrinol Metab.* 28, 104-120.
- 47 Pike JW, Meyer MB, Benkusky NA, Lee SM, St John H, Carlson A, Onal M, Shamsuzzaman S. 2016. Genomic Determinants of Vitamin D-Regulated Gene Expression. *Vitam Horm.* 100:21-44.
- 48 Meyer MB, Benkusky NA, Sen B, Rubin J, Pike JW. 2016. Epigenetic Plasticity Drives Adipogenic and Osteogenic Differentiation of Marrow-derived Mesenchymal Stem Cells. *J Biol Chem.* 291, 17829-17847.
- 49 Meyer MB, Benkusky NA, Lee CH, Pike JW. Genomic determinants of gene regulation by 1,25-dihydroxyvitamin D3 during osteoblast-lineage cell differentiation. 2014. *The Journal of Biological Chemistry.* 289, 19539–19554.
- 50 St John HC, Bishop KA, Meyer MB, Benkusky NA, Leng N, Kendzierski C, Bonewald LF, Pike JW. 2014. The osteoblast to osteocyte transition: Epigenetic changes and response to the vitamin D3 hormone. *Molecular Endocrinology.* 28, 1150–1165.
- 51 St John HC, Meyer MB, Benkusky NA, Carlson AH, Prideaux M, Bonewald LF, Pike JW. 2015. The parathyroid hormone-regulated transcriptome in osteocytes: Parallel actions with 1,25-dihydroxyvitamin D3 to oppose gene expression changes during differentiation and to promote mature cell function. *Bone.* 72:81-91.
- 52 Pike JW. 2011. Genome-wide principles of gene regulation by the vitamin D receptor and its activating ligand. *Mol Cell Endocrinol.* 347, 3-10.
- 53 Student AK, Hsu RY, Lane MD. 1980. Induction of fatty acid synthetase synthesis in differentiating 3T3-L1 preadipocytes. *J. Biol. Chem.* 255, 4745-4750.
54. Cristancho AG, Lazar MA. 2011. Forming functional fat: a growing understanding of adipocyte differentiation. *Nat. Rev. Mol. Cell Biol.* 12, 722–734.
55. Siersbæk R, Nielsen R, Mandrup S. 2012. Transcriptional networks and chromatin remodeling controlling adipogenesis. *Trends Endocrinol. Metab.* 23, 56–64.

- 56 Tang QQ, Otto TC, Lane MD. 2003. CCAAT/enhancer-binding protein beta is required for mitotic clonal expansion during adipogenesis. *Proc. Natl. Acad. Sci. U.S.A.* 100, 850–855.
- 57 Hida Y, Kawada T, Kayahashi S, Ishihara T, Fushiki T. 1998. Counteraction of retinoic acid and 1,25-dihydroxyvitamin D3 on up-regulation of adipocyte differentiation with PPARgamma ligand, an antidiabetic thiazolidinedione, in 3T3-L1 cells. *Life Sci.* 62:PL205-11.
- 58 Sakuma T, Miyamoto T, Jiang W, Kakizawa T, Nishio SI, Suzuki S, Takeda T, Oiwa A, Hashizume K. 2003. Inhibition of peroxisome proliferator-activated receptor alpha signaling by vitamin D receptor. *Biochem. Biophys. Res. Commun.* 312, 513–519.
- 59 Kelly KA, Gimble JM. 1998. 1,25-Dihydroxy vitamin D3 inhibits adipocyte differentiation and gene expression in murine bone marrow stromal cell clones and primary cultures. *Endocrinology.* 139, 2622-2628.
- 60 Bellows CG, Wang YH, Heersche JN, Aubin JE. 1994. 1,25-dihydroxyvitamin D3 stimulates adipocyte differentiation in cultures of fetal rat calvaria cells: comparison with the effects of dexamethasone. *Endocrinology.* 134, 2221–2229.
- 61 Bellows CG, Heersche JN. 2001. The frequency of common progenitors for adipocytes and osteoblasts and of committed and restricted adipocyte and osteoblast progenitors in fetal rat calvaria cell populations. *J. Bone Miner. Res.* 16, 1983-1993.
- 62 Zhang S, Chan M, Aubin JE. 2006. Pleiotropic effects of the steroid hormone 1,25-dihydroxyvitamin D3 on the recruitment of mesenchymal lineage progenitors in fetal rat calvaria cell populations. *J. Mol. Endocrinol.* 36, 425–433.
- 63 Atmani H, Chappard D, Basle MF. 2003. Proliferation and differentiation of osteoblasts and adipocytes in rat bone marrow stromal cell cultures: effects of dexamethasone and calcitriol. *J. Cell Biochem.* 89, 364–372.
- 64 Narvaez CJ, Simmons KM, Brunton J, Salinero A, Chittur SV, Welsh JE. 2013. Induction of STEAP4 correlates with 1,25-dihydroxyvitamin D3 stimulation of adipogenesis in mesenchymal progenitor cells derived from human adipose tissue. *J Cell Physiol.* 228, 2024-2036.

- 65 Horton JD, Goldstein JL, Brown MS. 2002. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. *J Clin Invest.* 109, 1125–1131.
- 66 Bennett MK, Seo Y-K, Datta S, Shin D-J, Osborne TF. 2008. Selective Binding of SREBP isoforms and Co-Regulatory Proteins to Promoters for Lipid Metabolic Genes in Liver. *J. Biol. Chem.* 283, 15628–15637.
- 67 Sheng Z, Otani H, Brown MS, Goldstein JL. 1995. Independent regulation of sterol regulatory element binding proteins 1 and 2 in hamster liver. *Proc. Natl. Acad. Sci. USA.* 92, 935–938.
- 68 Horton JD, Bashmakov Y, Shimomura I, Shimano H. 1998. Regulation of sterol regulatory element binding proteins in livers of fasted and refed mice. *Proc. Natl. Acad. Sci. USA.* 95, 5987–5992.
- 69 Seo YK, Jeon TI, Chong HK, Biesinger J, Xie X, Osborne TF. 2011. Genome-wide Localization of SREBP-2 in Hepatic Chromatin Predicts a Role in Autophagy. *Cell metab.* 13, 367–375.
- 70 Bhat M, Noolu B, Qadri SS, Ismail A. 2014. Vitamin D deficiency decreases adiposity in rats and causes altered expression of uncoupling proteins and steroid receptor coactivator3. *J. Steroid Biochem. Mol. Biol.* 144, 304-312.
- 71 Bhat M, Kalam R, Qadri SS, Madabushi S, Ismail A. 2013. Vitamin D deficiency-induced muscle wasting occurs through the ubiquitin proteasome pathway and is partially corrected by calcium in male rats. *Endocrinology.* 154, 4018–4029.
- 72 Bastie CC, Gaffney-Stomberg E, Lee TW, Dhima E, Pessin JE, Augenlicht LH. 2012. Dietary cholecalciferol and calcium levels in a Western-style defined rodent diet alter energy metabolism and inflammatory responses in mice. *J. Nutr.* 142, 859-865.
- 73 Marcotorchino J, Tourniaire F, Astier J, Karkeni E, Canault M, Amiot MJ, Bendahan D, Bernard M, Martin JC, Giannesini B, Landrier JF. 2014. Vitamin D protects against diet-induced obesity by enhancing fatty acid oxidation. *J. Nutr. Biochem.* 25, 1077-1083.
- 74 Yin Y, Yu Z, Xia M, Luo X, Lu X, Ling W. 2012. Vitamin D attenuates high fat diet-induced hepatic steatosis in rats by modulating lipid metabolism. *Eur. J. Clin. Invest.* 42, 1189-1196.

- 75 Yao Y, Zhu L, He L, Duan Y, Liang W, Nie Z, Jin Y, Wu X, Fang Y. 2015. A meta-analysis of the relationship between vitamin D deficiency and obesity. *Int. J. Clin. Exp. Med.* 8, 14977-14984.
- 76 Pereira-Santos M, Costa PR, Assis AM, Santos CA, Santos DB. 2015. Obesity and vitamin D deficiency: a systematic review and meta-analysis. *Obes. Rev.* 16, 341–349.
- 77 Sadiya A, Ahmed SM, Skaria S, Abusnana S. 2014. Vitamin D status and its relationship with metabolic markers in persons with obesity and type 2 diabetes in the UAE: a cross-sectional study. *J. Diabetes Res.* 2014, 869307.
- 78 González L, Ramos-Trautmann G, Díaz-Luquis GM, Pérez CM, Palacios C. 2015. Vitamin D status is inversely associated with obesity in a clinic-based sample in Puerto Rico. *Nutr. Res.* 35, 287-293.
- 79 Rusconi RE, De Cosmi V, Gianluca G, Giavoli C, Agostoni C. 2015. Vitamin D insufficiency in obese children and relation with lipid profile. *Int. J. Food Sci. Nutr.* 66, 132-134.
- 80 Young KA, Engelman CD, Langefeld CD, Hairston KG, Haffner SM, Bryer-Ash M, Norris JM. 2009. Association of plasma vitamin D levels with adiposity in Hispanic and African Americans. *J. Clin. Endocrinol. Metab.* 94, 3306–3313.
- 81 Goldner WS, Stoner JA, Thompson J, Taylor K, Larson L, Erickson J, McBride C. 2008. Prevalence of vitamin D insufficiency and deficiency in morbidly obese patients: a comparison with non-obese controls. *Obes. Surg.* 18, 145–150.
- 82 Wamberg L, Christiansen T, Paulsen SK, Fisker S, Rask P, Rejnmark L, Richelsen B, Pedersen SB. 2013. Expression of vitamin D-metabolizing enzymes in human adipose tissue -- the effect of obesity and diet-induced weight loss. *Int. J. Obes. (Lond).* 37, 651-657.
- 83 Vimalaswaran KS, Berry DJ, Lu C, Tikkanen E, Pilz S, Hiraki LT, Cooper JD, Dastani Z, *et al.* 2013. Causal relationship between obesity and vitamin D status: bi-directional Mendelian randomization analysis of multiple cohorts. *PLoS Med.* 10, e1001383.

- 84 Jamka M, Woźniewicz M, Jeszka J, Mardas M, Bogdański P, Stelmach-Mardas M. 2015. The effect of vitamin D supplementation on insulin and glucose metabolism in overweight and obese individuals: systematic review with meta-analysis. *Sci. Rep.* 5, 16142-16154.
- 85 Wamberg L, Pedersen SB, Rejnmark L, Richelsen B. 2015. Causes of Vitamin D Deficiency and Effect of Vitamin D Supplementation on Metabolic Complications in Obesity: a Review. *Curr. Obes. Rep.* 4, 429-440.
- 86 Chandler PD, Wang L, Zhang X, Sesso HD, Moorthy MV, Obi O, Lewis J, Prince RL, Danik JS, Manson JE, LeBoff MS, Song Y. 2015. Effect of vitamin D supplementation alone or with calcium on adiposity measures: a systematic review and meta-analysis of randomized controlled trials. *Nutr. Rev.* 73, 577-593.
- 87 Sadiya A, Ahmed SM, Carlsson M, Tesfa Y, George M, Ali SH, Siddieg HH, Abusnana S. 2016. Vitamin D supplementation and body composition in persons with obesity and type 2 diabetes in the UAE: A randomized controlled double-blinded clinical trial. *Clin. Nutr.* 35, 77-82.
- 88 Pannu PK, Calton EK, Soares MJ. 2016. Calcium and Vitamin D in Obesity and Related Chronic Disease. *Adv Food Nutr Res.* 77, 57-100.
- 89 Zhu W, Cai D, Wang Y, Lin N, Hu Q, Qi Y, Ma S, Amarasekara S. 2013. Calcium plus vitamin D3 supplementation facilitated fat loss in overweight and obese college students with very-low calcium consumption: a randomized controlled trial. *Nutr J.* 12, 1-8.
- 90 Rosenblum JL, Castro VM, Moore CE, Kaplan LM. 2012. Calcium and vitamin D supplementation is associated with decreased abdominal visceral adipose tissue in overweight and obese adults. *Am J Clin Nutr.* 95, 101-108.
- 91 Asemi Z, Foroozanfard F, Hashemi T, Bahmani F, Jamilian M, Esmailzadeh A. 2015. Calcium plus vitamin D supplementation affects glucose metabolism and lipid concentrations in overweight and obese vitamin D deficient women with polycystic ovary syndrome. *Clin Nutr.* 34, 586-592.

Figure legend

Figure 1. Schematic presentation of the consequences of mitochondrial activity of VDR on lipid metabolism. (A) VDR overexpression downregulates electron transport chain (ETC) and uncoupling protein (UCP) expression; the decreased utilization of reducing units NADH and FADH₂ slows down beta-oxidation. Mitochondrial activity of VDR decreases lipid catabolism and promotes the channeling of acetyl-CoA into biosynthetic pathways, whilst the mitochondrial import of fatty acids (FA) through carnitine acyltransferase (CAT) is inhibited by the biosynthetic precursor malonyl-CoA. (B) The loss of VDR activity reinforces ETC activity and UCP expression; TCA cycle and beta-oxidation are enhanced to fuel the boosted respiratory chain. When most of the mitochondrial acetyl-CoA is consumed by TCA cycle, very low levels are available in cytosol for acetyl-CoA carboxylase to synthesize malonyl-CoA, the precursor of the biosynthetic pathway of lipids. The transport of fatty acid toward mitochondrial matrix increases because malonyl-CoA no longer inhibits CAT. AS: ATP synthase.

Figure 2. The dual effect of 1,25(OH)₂D₃ on adipogenesis. The mitochondrial effects of 1,25(OH)₂D₃ support the nuclear program. (A) In proliferating preadipocyte cell line, in the early phase of a differentiation protocol the cultural stimulation maintains the cells in a proliferative condition and VDR cistrome adapts to the epigenetic profile imposed by the proliferative context. In addition, the mitochondrial effects of 1,25(OH)₂D₃ support cell growth by shifting acetyl-CoA from the oxidative metabolism toward cholesterol biosynthesis. As consequence, 1,25(OH)₂D₃ treatment in the early phase of differentiation facilitates proliferation and decreases lipid deposition. (B) In primary cultures of cells that are committed to the adipocyte lineage, VDR fits the chromatin remodeling induced by the differentiation program and modulates differentiation-specific gene sets. In this genomic background that promotes adipogenesis, 1,25(OH)₂D₃ enhances lipid deposition because the mitochondrial acetyl-CoA can be diverted toward the synthesis of fatty acids. ETC: electron transport chain; AS: ATP synthase.




Figure 1




Figure 2